tiprankstipranks
Trending News
More News >
Goodbody Health (GDBYF)
OTHER OTC:GDBYF
US Market
Advertisement

Goodbody Health (GDBYF) Ratios

Compare
46 Followers

Goodbody Health Ratios

GDBYF's free cash flow for Q3 2022 was C$0.45. For the 2022 fiscal year, GDBYF's free cash flow was decreased by C$ and operating cash flow was C$-0.52. See a summary of the company’s cash flow.
Ratios
TTM
Dec 21Dec 20Dec 19Sep 18
Liquidity Ratios
Current Ratio
2.03 2.00 4.50--
Quick Ratio
1.87 1.74 4.16--
Cash Ratio
1.69 1.30 3.32--
Solvency Ratio
-0.34 -2.18 -3.37--
Operating Cash Flow Ratio
0.52 -1.63 -4.36--
Short-Term Operating Cash Flow Coverage
0.00 0.00 0.00--
Net Current Asset Value
C$ 3.52MC$ 963.33KC$ 1.65M--
Leverage Ratios
Debt-to-Assets Ratio
0.03 0.06 0.14--
Debt-to-Equity Ratio
0.05 0.08 0.18--
Debt-to-Capital Ratio
0.05 0.07 0.15--
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00--
Financial Leverage Ratio
1.53 1.31 1.30--
Debt Service Coverage Ratio
0.00 -147.72 0.00--
Interest Coverage Ratio
0.00 -165.28 0.00--
Debt to Market Cap
0.00 0.00 0.00--
Interest Debt Per Share
<0.01 0.03 0.08--
Net Debt to EBITDA
417.21 0.33 0.42--
Profitability Margins
Gross Profit Margin
52.36%56.35%52.03%--
EBIT Margin
-6.19%-230.23%-245.12%--
EBITDA Margin
-0.08%-206.59%-227.21%--
Operating Profit Margin
-6.19%-223.96%-229.03%--
Pretax Profit Margin
-13.17%-240.04%-261.99%--
Net Profit Margin
-13.57%-233.61%-261.99%--
Continuous Operations Profit Margin
-13.57%-233.58%-261.99%--
Net Income Per EBT
103.01%97.32%100.00%--
EBT Per EBIT
212.65%107.18%114.39%--
Return on Assets (ROA)
-21.34%-56.75%-83.43%--
Return on Equity (ROE)
-34.66%-74.13%-108.48%--
Return on Capital Employed (ROCE)
-14.57%-66.00%-84.01%--
Return on Invested Capital (ROIC)
-14.70%-62.67%-85.50%--
Return on Tangible Assets
-22.60%-69.23%-95.42%--
Earnings Yield
-895708.03%-4087.62%-1935.06%--
Efficiency Ratios
Receivables Turnover
40.38 11.19 4.98--
Payables Turnover
0.00 0.00 0.00--
Inventory Turnover
13.81 2.30 3.35--
Fixed Asset Turnover
5.79 0.52 1.19--
Asset Turnover
1.57 0.24 0.32--
Working Capital Turnover Ratio
6.62 1.12 1.35--
Cash Conversion Cycle
35.48 191.25 182.42--
Days of Sales Outstanding
9.04 32.61 73.36--
Days of Inventory Outstanding
26.44 158.64 109.06--
Days of Payables Outstanding
0.00 0.00 0.00--
Operating Cycle
35.48 191.25 182.42--
Cash Flow Ratios
Operating Cash Flow Per Share
0.05 -0.14 -0.33--
Free Cash Flow Per Share
0.05 -0.16 -0.39--
CapEx Per Share
<0.01 0.02 0.07--
Free Cash Flow to Operating Cash Flow
0.86 1.10 1.20--
Dividend Paid and CapEx Coverage Ratio
7.32 -9.55 -4.97--
Capital Expenditure Coverage Ratio
7.32 -9.55 -4.97--
Operating Cash Flow Coverage Ratio
5.51 -4.70 -4.21--
Operating Cash Flow to Sales Ratio
0.11 -1.18 -1.80--
Free Cash Flow Yield
588043.77%-2275.98%-1599.11%--
Valuation Ratios
Price-to-Earnings (P/E) Ratio
>-0.01 -0.02 -0.05--
Price-to-Sales (P/S) Ratio
<0.01 0.06 0.14--
Price-to-Book (P/B) Ratio
<0.01 0.02 0.06--
Price-to-Free Cash Flow (P/FCF) Ratio
<0.01 -0.04 -0.06--
Price-to-Operating Cash Flow Ratio
<0.01 -0.05 -0.08--
Price-to-Earnings Growth (PEG) Ratio
<0.01 <0.01 >-0.01--
Price-to-Fair Value
<0.01 0.02 0.06--
Enterprise Value Multiple
417.19 0.31 0.36--
Enterprise Value
-5.73M -1.26M -1.18M--
EV to EBITDA
417.19 0.31 0.36--
EV to Sales
-0.34 -0.63 -0.81--
EV to Free Cash Flow
-3.58 0.49 0.37--
EV to Operating Cash Flow
-3.09 0.54 0.45--
Tangible Book Value Per Share
0.19 0.30 0.37--
Shareholders’ Equity Per Share
0.20 0.39 0.44--
Tax and Other Ratios
Effective Tax Rate
-0.03 0.03 -0.06--
Revenue Per Share
0.49 0.12 0.18--
Net Income Per Share
-0.07 -0.29 -0.48--
Tax Burden
1.03 0.97 1.00--
Interest Burden
2.13 1.04 1.07--
Research & Development to Revenue
0.00 0.00 0.00--
SG&A to Revenue
0.25 2.38 2.44--
Stock-Based Compensation to Revenue
0.02 0.55 0.50--
Income Quality
-0.83 0.49 0.69--
Currency in CAD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis